Trials / Completed
CompletedNCT00910858
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | Lenalidomide 5-mg capsules for oral administration |
| DRUG | Recombinant human erythropoietin | Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units. |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-04-01
- Completion
- 2009-05-01
- First posted
- 2009-06-01
- Last updated
- 2013-09-30
- Results posted
- 2013-09-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00910858. Inclusion in this directory is not an endorsement.